Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea.

Abstract

Transvenous phrenic nerve stimulation improved sleep metrics and quality of life after 6 months versus control in the remedē System Pivotal Trial. This analysis explored the effectiveness of phrenic nerve stimulation in patients with central sleep apnea after 12 months of therapy. Reproducibility of treatment effect was assessed in the former control group in whom the implanted device was initially inactive for the sixth month and subsequently activated when the randomized control assessments were complete. Patients with moderate-to-severe central sleep apnea implanted with the remedē System were randomized to therapy activation at 1 month (treatment) or after 6 months (control). Sleep indices were assessed from baseline to 12 months in the treatment group and from 6 to 12 months in former controls. In the treatment group, a ≥50% reduction in apnea-hypopnea index occurred in 60% of patients at 6 months (95% confidence interval [CI] 47% to 64%) and 67% (95% CI 53% to 78%) at 12 months. After 6 months of therapy, 55% of former controls (95% CI 43% to 67%) achieved ≥50%reduction in apnea-hypopnea index. Patient Global Assessment was markedly ormoderately improved at 6 and 12 months in 60% of treatment patients.Improvements persisted at 12 months. A serious adverse event within 12 months occurred in 13 patients (9%). Phrenic nerve stimulation produced sustained improvements in sleep indices and quality of life to at least 12 months in patients with central sleep apnea. The similar improvement of former controls after 6 months of active therapy confirms benefits are reproducible and reliable.

• Authors: Maria Rosa Costanzo, Piotr Ponikowski, Shahrokh Javaheri, Ralph Augostini, Lee R Goldberg, Richard Holcomb, Andrew Kao, Rami N Khayat, Olaf Oldenburg, Christoph Stellbrink, William T Abraham, remedē System Pivotal Trial Study Group
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 121 Issue 11 Pg. 1400-1408 (06 01 2018) ISSN: 1879-1913 [Electronic] United States
• PMID: 29735217 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 Respicardia, Inc. Published by Elsevier Inc. All rights reserved.

Topics

• Aged
• Electric Stimulation Therapy (methods)
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Phrenic Nerve
• Polysomnography
• Prospective Studies
• Quality of Life
• Reproducibility of Results
• Severity of Illness Index
• Sleep Apnea, Central (physiopathology, therapy)
• Treatment Outcome